daklizumab [Daclizumab]

tematický
6
Termíny

daclizumab
Zenapax
Zinbryta

 

Dacliximab
Ro 24-7375
Ro-24-7375
Zenapax
Zinbryta

Perzistentní odkaz   https://www.medvik.cz/link/D000077561
Definice

Imunosupresivum, rekombinantní, humanizovaná protilátka anti-Tac, antagonista receptoru interleukinu 2. Inhibuje interleukinem-2 zprostředkovanou aktivaci lymfocytů, což je kritická cesta v buněčné imunitní odpovědi účastnící se rejekce allogenního štěpu. Užívá se k profylaxi akutní orgánové rejekce u pacientů po allogenní renální transplantaci. (cit. Velký lékařský slovník online, 2018 http://lekarske.slovniky.cz/ )

An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS.

DUI
D000077561 MeSH Prohlížeč
CUI
M0252703
Historická pozn.
2019 (1995)
Veřejná pozn.
2019; DACLIZUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2012-2018; and under ANTIBODIES, MONOCLONAL 1995-2011

Povolená podhesla

AN
analýza
AD
aplikace a dávkování
BI
biosyntéza
CH
chemie
HI
dějiny
EC
ekonomika
PK
farmakokinetika
PD
farmakologie 1
PH
fyziologie
GE
genetika
IM
imunologie
IP
izolace a purifikace
CL
klasifikace
BL
krev
ME
metabolismus
UR
moč
CF
mozkomíšní mok
PO
otrava
AE
škodlivé účinky 2
TU
terapeutické užití 1
TO
toxicita
DE
účinky léků
RE
účinky záření
UL
ultrastruktura

D Chemikálie a léčiva
D12 aminokyseliny, peptidy a proteiny 16
D12.776 proteiny 2 596
D12.776.124 krevní proteiny 911
D12.776.124.486 imunoproteiny 14
D12.776.124.486.485 imunoglobuliny 1 498
D12.776.124.486.485.114 protilátky 1 820
D12.776.124.486.485.114.224 monoklonální protilátky 4 742
D12.776.124.486.485.114.224.060 humanizované monoklonální protilátky 3 045
D12.776.124.486.485.114.224.060.125 abciximab 14
D12.776.124.486.485.114.224.060.250 adalimumab 359
D12.776.124.486.485.114.224.060.313 alemtuzumab 127
D12.776.124.486.485.114.224.060.344 basiliximab 2
D12.776.124.486.485.114.224.060.375 bevacizumab 461
D12.776.124.486.485.114.224.060.438 brentuximab vedotin 45
D12.776.124.486.485.114.224.060.500 certolizumab pegol 50
D12.776.124.486.485.114.224.060.750 cetuximab 186
D12.776.124.486.485.114.224.060.766 daklizumab 6
D12.776.124.486.485.114.224.060.782 denosumab 164
D12.776.124.486.485.114.224.060.790 gemtuzumab 20
D12.776.124.486.485.114.224.060.794 inotuzumab ozogamicin 12
D12.776.124.486.485.114.224.060.798 ipilimumab 276
D12.776.124.486.485.114.224.060.813 natalizumab 162
D12.776.124.486.485.114.224.060.829 nivolumab 475
D12.776.124.486.485.114.224.060.844 omalizumab 118
D12.776.124.486.485.114.224.060.860 palivizumab 14
D12.776.124.486.485.114.224.060.864 panitumumab 62
D12.776.124.486.485.114.224.060.866 ramucirumab 1
D12.776.124.486.485.114.224.060.868 ranibizumab 63
D12.776.124.486.485.114.224.060.875 trastuzumab 282
D12.776.124.486.485.114.224.060.937 ustekinumab 127
D12.776.124.790 sérové globuliny 62
D12.776.124.790.651 imunoglobuliny 1 498
D12.776.124.790.651.114 protilátky 1 820
D12.776.124.790.651.114.224 monoklonální protilátky 4 742
D12.776.124.790.651.114.224.060 humanizované monoklonální protilátky 3 045
D12.776.124.790.651.114.224.060.125 abciximab 14
D12.776.124.790.651.114.224.060.250 adalimumab 359
D12.776.124.790.651.114.224.060.375 alemtuzumab 127
D12.776.124.790.651.114.224.060.407 basiliximab 2
D12.776.124.790.651.114.224.060.438 bevacizumab 461
D12.776.124.790.651.114.224.060.469 brentuximab vedotin 45
D12.776.124.790.651.114.224.060.500 certolizumab pegol 50
D12.776.124.790.651.114.224.060.750 cetuximab 186
D12.776.124.790.651.114.224.060.766 daklizumab 6
D12.776.124.790.651.114.224.060.782 denosumab 164
D12.776.124.790.651.114.224.060.790 gemtuzumab 20
D12.776.124.790.651.114.224.060.794 inotuzumab ozogamicin 12
D12.776.124.790.651.114.224.060.798 ipilimumab 276
D12.776.124.790.651.114.224.060.813 natalizumab 162
D12.776.124.790.651.114.224.060.829 nivolumab 475
D12.776.124.790.651.114.224.060.844 omalizumab 118
D12.776.124.790.651.114.224.060.860 palivizumab 14
D12.776.124.790.651.114.224.060.864 panitumumab 62
D12.776.124.790.651.114.224.060.866 ramucirumab 1
D12.776.124.790.651.114.224.060.868 ranibizumab 63
D12.776.124.790.651.114.224.060.875 trastuzumab 282
D12.776.124.790.651.114.224.060.937 ustekinumab 127
D12.776.377 globuliny 68
D12.776.377.715 sérové globuliny 62
D12.776.377.715.548 imunoglobuliny 1 498
D12.776.377.715.548.114 protilátky 1 820
D12.776.377.715.548.114.224 monoklonální protilátky 4 742
D12.776.377.715.548.114.224.200 humanizované monoklonální protilátky 3 045
D12.776.377.715.548.114.224.200.125 abciximab 14
D12.776.377.715.548.114.224.200.250 adalimumab 359
D12.776.377.715.548.114.224.200.375 alemtuzumab 127
D12.776.377.715.548.114.224.200.407 basiliximab 2
D12.776.377.715.548.114.224.200.438 bevacizumab 461
D12.776.377.715.548.114.224.200.469 brentuximab vedotin 45
D12.776.377.715.548.114.224.200.500 certolizumab pegol 50
D12.776.377.715.548.114.224.200.750 cetuximab 186
D12.776.377.715.548.114.224.200.766 daklizumab 6
D12.776.377.715.548.114.224.200.782 denosumab 164
D12.776.377.715.548.114.224.200.790 gemtuzumab 20
D12.776.377.715.548.114.224.200.794 inotuzumab ozogamicin 12
D12.776.377.715.548.114.224.200.798 ipilimumab 276
D12.776.377.715.548.114.224.200.813 natalizumab 162
D12.776.377.715.548.114.224.200.829 nivolumab 475
D12.776.377.715.548.114.224.200.844 omalizumab 118
D12.776.377.715.548.114.224.200.860 palivizumab 14
D12.776.377.715.548.114.224.200.864 panitumumab 62
D12.776.377.715.548.114.224.200.866 ramucirumab 1
D12.776.377.715.548.114.224.200.868 ranibizumab 63
D12.776.377.715.548.114.224.200.875 trastuzumab 282
D12.776.377.715.548.114.224.200.937 ustekinumab 127

daclizumab HYP Chemical MeSH Prohlížeč

Přidat